Stopping bread and baked goods for five days will improve 85% of reflux and IBS symptoms within at most ten days; both diseases can be eliminated completely.
Original statement
لو بطلوا انهارددة العيش البلدي والمخبوزات بتضيق الصافي لمدة خمسة ايام خمسة وثمانون في المائة من اعراض الارتجاع وأراض القانون العصبي هتحسن [01:27] عصبي هتتحسن انمكنش هتروح كلها لحد اقصي. عشرة ايام
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Stopping bread and baked goods for five days will improve 85% of reflux and IBS symptoms within at most ten days; both diseases can be eliminated completely.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- علاج الحموضة فى خطوة واحدة بس .. ماحدش فكر فيها قبل كده (Open source)
- Published
- 12 March 2021
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Archive transcript with time markers; wording partly garbled.
- Claimed mechanism
Removal of bread removes the cause.
- Claimed health effect
85% symptom improvement; complete cure.
- Population concerned
People with reflux and IBS.
- Geographic restriction by Elawady
none found
Diverging source versions
الحموضة أو ارتجاع المرئ والقولون العصبي مرضين في الجهاز الهضمي ممكن نتخلص منهم تماما لو بطلنا عادات سيئة كتير بنعملها في أكلنا لو شوية تحسين في التغذية بتاعتنا هتختفي كل الاعراض دي الحموضة العيانين بيشتكوا منها ويروحوا يتعلقوا منها بأدوية بتقلل الحموضة زي الرنتي دي [00:29] زي الرانيتيدين والكنترولات وبعد شوية يكتشفوا ان عندهم جرثوم حلزونية يااخدوا لي لها علاج لا الجرثومة بتخف ولا الارتجاع بيقل مجر ما يوقف الدوااء النهارده الارتجاع بيزيد
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- علاج الحموضة فى خطوة واحدة بس .. ماحدش فكر فيها قبل كده (Open source)
- Published
- 12 March 2021
- Timestamp
- not available (transcript has no timings)
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
85% improvement in 5–10 days after stopping bread; complete elimination of reflux and IBS.
2. What is demonstrably correct?
Some patients improve with dietary change (see C-GUT-01).
3. What is wrong or exaggerated?
The 85% figure has no identified source. The statement that both diseases can be 'eliminated completely' through habits contradicts guidelines that recommend drugs, psychotherapy and other measures because diet alone often does not suffice.
4. What remains unclear?
Elawady's clinical experience is not documented in a published, controlled form.
5. Which studies support it?
None.
6. Which studies contradict it?
ACG IBS 2021 (I-GUT-05) and ACG GERD 2022 (I-PPI-10) recommend multiple treatment options beyond diet. Gluten-free diet RCT: 58% responders at 4 weeks (I-GUT-103); blinded wheat vs sham challenge: no significant difference (39% vs 29% worsening; I-GUT-120); IBS placebo response 27.3% (I-GUT-104); diet NMA (I-GUT-102); lifestyle explains about 37% of GERD symptoms in a large cohort (I-GUT-105). NICE NG12 and CG184 require investigation of alarm symptoms (I-GUT-109, I-GUT-108).
7. What applies to Germany and Europe?
Not applicable.
8. What is known about Egypt?
Not applicable.
9. What practical conclusion is appropriate?
Promises of fast, near-universal cure should be viewed critically; persistent or alarm symptoms need medical evaluation.
Assessment details
- Rationale for certainty of evidence
No source for the 85% figure exists. Randomised data now contradict it directly: in the closest trial a gluten-free (wheat-free) diet gave 58% responders after 4 weeks (95% CI 41%-73%; I-GUT-103), a network meta-analysis of 28 RCTs shows diets help a proportion of IBS patients, not nearly all (I-GUT-102), a blinded wheat challenge was not worse than sham in IBS patients who believed wheat harmed them (I-GUT-120), and placebo responses of 27-34% in IBS trials show why uncontrolled success rates are inflated (I-GUT-104). Certainty is moderate because no trial tested the exact regimen.
- Source quality
Quantitative promise without evidence.
- Regional transferability
n/a
- Individual exceptions
Some individuals may improve strongly.
- Regional scope of the claim
- not specified
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).
Research question: In people with reflux or IBS, does stopping bread and baked goods for five days improve symptoms in about 85% within 10 days, and can the diseases be eliminated completely?
Research question in detail (PICO)
- Population
- Adults with GERD or IBS
- Intervention or exposure
- Stopping bread/baked goods
- Comparison
- Habitual diet; sham/placebo; other diets
- Geographic scope
- universal biology
- Outcomes
- Responder rate
- Time to response
- Remission/cure
- Safety (missed alarm symptoms)
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Three diets for IBS worked about equally
Rej A et al.. Clin Gastroenterol Hepatol 2022 · PMID 35240330 · DOI 10.1016/j.cgh.2022.02.045 Randomised controlled trialabstract checkednewly addedThe closest trial (gluten-free diet) shows improvement in a majority of IBS patients after 4 weeks, though not 85%.
- Actual result
- 58% (19/33) responders; Wilson CI 41%-73%
- Methodological quality
- moderate (small RCT)
- Relevance
- direct
- Limitations
- No untreated control; 4 weeks, not 10 days
What speaks against the claim?
In a blind test, wheat was not clearly worse than a fake
Seiler CL et al.. Lancet Gastroenterol Hepatol 2025 · PMID 40706614 · DOI 10.1016/S2468-1253(25)00090-1 Randomised controlled trialabstract checkednewly addedBlinded re-challenge: wheat no worse than sham in IBS patients who believed wheat caused symptoms; expectations played a major role.
- Actual result
- Worsening 39% wheat vs 29% sham (RD 0.11, -0.16 to 0.35)
- Methodological quality
- high internal validity, imprecise
- Relevance
- direct
- Limitations
- n=28
Many IBS patients improve on placebo
Bosman M et al.. Lancet Gastroenterol Hepatol 2021 · PMID 33765447 · DOI 10.1016/S2468-1253(21)00023-6 Meta-analysisabstract checkednewly addedAbout a quarter to a third of IBS patients improve on placebo, so uncontrolled success rates are inflated.
- Actual result
- Placebo response 27.3% (24.3-30.9) global; 34.4% pain
- Methodological quality
- high (meta-analysis of 73 RCTs)
- Relevance
- indirect (drug trials)
- Limitations
- Heterogeneity
Warning signs that need a doctor
National Institute for Health and Care Excellence (NICE). NICE guideline NG12 2015 (last updated 15 April 2026) Guideline / position statementfull text checkednewly addedNICE NG12: dysphagia, weight loss with reflux at 55+, haematemesis require referral or endoscopy.
- Actual result
- Referral criteria
- Methodological quality
- official guideline
- Relevance
- direct for the safety aspect
- Limitations
- UK thresholds
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
The 85%-in-10-days figure and the promise of complete elimination are not supported; diet helps a part of patients over weeks, and guidelines require investigation of alarm symptoms.
Why some studies weigh more
Randomised and blinded data and placebo-response data outweigh unpublished clinical impressions; no source for the 85% figure was found.
Is a causal relationship established? Not established No controlled study tested the specific regimen; the best related RCT shows lower response rates and blinded data attribute much of perceived wheat effects to expectation.
Remaining uncertainty
Response of Egyptian patients to bread removal was never studied.
Justified conclusion
The quantitative promise is unsupported and the 'complete elimination' statement contradicts guidelines; diet is one part of care.
Why do studies seem to disagree?
No real conflict: supportive data show partial response, not cure; the claim's figure appears to derive from uncontrolled observation.
Does this depend on the country?
- General biological effects
- Universal human physiology.
- Eating habits
- Not decisive for this claim.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Not relevant.
- Legal rules
- Not relevant.
- Actual monitoring data
- Not applicable.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Is 85% compatible with trial response rates? – All Wilson 95% CIs (upper limits 59%-73%) exclude 85% recalculated
- Placebo response as benchmark – 27.3% (24.3-30.9) placebo response; uncontrolled rates cannot be attributed to diet not recalculable from the published data
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Proportion of patients with marked improvement or cure after stopping bread
- Starting level
- high (randomised trials)
- Reasons for downgrading
- indirectness (no trial of the exact regimen)
- imprecision (small trials)
- Result
- moderate
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- NICE: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184; I-GUT-108) (2014, updated 2019) · Original publication
Lifestyle advice (healthy eating, weight reduction, smoking cessation; avoid personal precipitants; main meal well before bed); step down PPIs to lowest effective dose or as-needed unless an underlying condition or comedication needs continuing treatment; same-day referral for dyspepsia with significant acute GI bleeding; long-term full-dose PPI after oesophageal stricture dilatation and as maintenance for severe oesophagitis; H. pylori eradication for H. pylori-positive peptic ulcer; PPI co-prescription with NSAIDs in high-risk people. - NICE: Suspected cancer: recognition and referral (NG12), upper GI section (I-GUT-109) (2015, page updated April 2026) · Original publication
Suspected cancer pathway referral for dysphagia, or age 55+ with weight loss plus upper abdominal pain, reflux or dyspepsia; consider endoscopy for haematemesis and for age 55+ with treatment-resistant dyspepsia or upper abdominal pain with low haemoglobin. - NICE: Irritable bowel syndrome in adults: diagnosis and management (CG61; I-GUT-110) (2008, updated 2017) · Original publication
Red-flag assessment and referral; regular meals; at least 8 cups of fluid per day, especially water; reduce alcohol and fizzy drinks; limiting high-fibre foods such as wholemeal/high-fibre flour and breads may help; exclusion diets such as low FODMAP only with a healthcare professional with dietary expertise. - ACG (American College of Gastroenterology): ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (Katz PO et al. 2022; I-PPI-10) (2022) · Original publication
Full text read: weight loss recommended for overweight/obese patients (strong, moderate evidence); avoid meals within 2-3 h of bedtime, avoid tobacco, avoid 'trigger foods', elevate head of bed for nocturnal symptoms (conditional, low evidence); Table 3 rates 'avoid carbonated beverages' as moderate evidence and recommendable; PPIs over H2RAs for healing erosive oesophagitis (strong, high evidence); attempt to discontinue PPIs in patients without erosive oesophagitis or Barrett's whose symptoms resolved (conditional, low); maintenance PPI indefinitely or surgery for LA grade C/D oesophagitis (strong, moderate); endoscopy first for dysphagia or alarm symptoms (weight loss, GI bleeding); rebound shown in healthy controls but strong evidence for symptom increase after abrupt withdrawal in patients is lacking.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| PubMed (E-utilities esearch) | 26 October 2026 | (irritable bowel syndrome[mh]) AND (cure OR remission OR "complete resolution") AND diet[tiab] AND randomized controlled trial[pt] | supporting evidence | 6 | |
| Europe PMC | 26 October 2026 | TITLE:"traditional dietary advice" AND TITLE:"gluten-free" | supporting evidence | 2 | |
| PubMed (E-utilities esearch) | 26 October 2026 | (gastroesophageal reflux[mh] OR irritable bowel syndrome[mh]) AND (bread OR wheat OR gluten OR "soft drinks" OR carbonated) AND randomized controlled trial[pt] | both directions | 107 | |
| Europe PMC | 26 October 2026 | TITLE:"placebo response" AND TITLE:"irritable bowel" AND (meta-analysis) | contradicting evidence | 7 | |
| Europe PMC | 26 October 2026 | ("irritable bowel") AND placebo AND ("placebo response") AND "meta-analysis" | contradicting evidence | 487 | |
| Europe PMC | 26 October 2026 | TITLE:"irritable bowel" AND TITLE:(diet OR dietary) AND TITLE:"network meta-analysis" | supporting evidence | 7 | |
| Europe PMC | 26 October 2026 | TITLE:(reflux OR GERD OR heartburn) AND TITLE:(carbohydrate OR sugar OR starch) | supporting evidence | 17 | |
| Web (curl/WebFetch of guideline page) | 26 October 2026 | https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer | guidelines | 1 | |
| Web (curl/WebFetch of guideline page) | 26 October 2026 | https://www.nice.org.uk/guidance/cg184/chapter/1-Recommendations | guidelines | 1 | |
| Web (curl/WebFetch of guideline page) | 26 October 2026 | https://www.nice.org.uk/guidance/cg61/chapter/Recommendations | guidelines | 1 | |
| Web (curl/WebFetch of guideline page) | 26 October 2026 | https://pmc.ncbi.nlm.nih.gov/articles/PMC8754510/ (ACG 2022 GERD guideline full text; Europe PMC fullTextXML returned HTTP 500) | guidelines | 1 |
Open questions
None beyond C-GUT-01.
How deeply was this checked?
11 linked studies: 6 checked in full text (0 of them with a structured risk-of-bias assessment), 5 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly false (low)
- 26 October 2026 · Phase 4 (systematic evidence review) · Verdict changed: Mostly false (low) → Mostly false (moderate)
Certainty raised: direct randomised data now exist (gluten-free diet responder rates with CIs excluding 85%; blinded wheat challenge null; placebo response benchmark), consistently contradicting the quantitative promise.
New sources: I-GUT-103 I-GUT-104 I-GUT-120 I-GUT-102 I-GUT-109
In plain language
The video promises that 85 out of 100 people with reflux or irritable bowel will get better within ten days of stopping bread. No study shows this. In the closest trial, about half of IBS patients improved after four weeks without wheat, and in a blinded test wheat caused no more symptoms than a fake. Many people also feel better after any change because of expectation. Diet can help, but many people need other treatments, and warning signs must be checked by a doctor.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (10)
-
ACG IBS guideline
Lacy BE et al.. Am J Gastroenterol 2021 · PMID 33315591 · DOI 10.14309/ajg.0000000000001036Guideline / position statementindependent cross-checkabstract checkedA low-FODMAP diet trial is recommended, along with drugs and psychotherapy.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
IBS management.
- How was the study done?
Guideline.
- What was actually found?
Multiple therapies.
- What do the results mean in everyday life?
Diet helps some.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
Applicable.
-
ACG 2022 reflux guideline
Katz PO et al.. Am J Gastroenterol 2022 · PMID 34807007 · DOI 10.14309/ajg.0000000000001538Guideline / position statementindependent cross-checkfull text checked★ key studyWeight loss, avoiding late meals and trigger foods help; PPIs are best for erosive oesophagitis.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
GERD management.
- How was the study done?
Guideline.
- What was actually found?
Lifestyle + PPI recommendations.
- What do the results mean in everyday life?
Diet helps; drugs needed for erosive disease.
- What are the study's limitations?
Low evidence for some lifestyle advice.
- What does it say about Elawady's specific claim?
Mixed for diet claims; contradicts ban.
- Do the results apply to Germany and Europe?
Applicable.
-
Three diets for IBS worked about equally
Rej A et al.. Clin Gastroenterol Hepatol 2022 · PMID 35240330 · DOI 10.1016/j.cgh.2022.02.045Randomised controlled trialindependent cross-checkabstract checked★ key studyIn 99 IBS patients, about half improved meaningfully after 4 weeks on a gluten-free, low-FODMAP or standard advice diet.
Responder rates 42-58% after 4 weeks; CI excludes 85%
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare three IBS diets.
- How was the study done?
Randomised trial, 4 weeks.
- How many people, animals or samples were studied?
99 adults with IBS without constipation.
- What was actually found?
Responders 42%, 55%, 58%; no significant difference.
- How large was the observed effect?
Gluten-free 58% (19/33).
- What do the results mean in everyday life?
Removing wheat can help some people, but not most of them dramatically.
- What are the study's limitations?
Small, unblinded, no untreated group.
- What does it say about Elawady's specific claim?
Contradicts the 85% figure; supports partial benefit.
- Do the results apply to Germany and Europe?
UK data; applicable to Europe.
- What can explicitly not be concluded from this study?
Cannot show a cure or effects beyond 4 weeks.
-
Many IBS patients improve on placebo
Bosman M et al.. Lancet Gastroenterol Hepatol 2021 · PMID 33765447 · DOI 10.1016/S2468-1253(21)00023-6Meta-analysisindependent cross-checkabstract checkedAcross 73 trials, about 27% of IBS patients improved overall on dummy pills.
Uncontrolled improvement rates are inflated by placebo response (~27-34%)
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure the placebo response in IBS trials.
- How was the study done?
Meta-analysis of placebo arms.
- How many people, animals or samples were studied?
73 randomised drug trials.
- What was actually found?
27% global improvement, 34% pain improvement on placebo.
- How large was the observed effect?
27.3% (24.3-30.9).
- What do the results mean in everyday life?
Feeling better after any change does not prove the change caused it.
- What are the study's limitations?
Drug trials only; heterogeneous.
- What does it say about Elawady's specific claim?
Shows the 85% figure from experience cannot be taken at face value.
- Do the results apply to Germany and Europe?
Applies everywhere.
- What can explicitly not be concluded from this study?
Cannot tell how much of a diet effect is placebo.
-
Which diets help irritable bowel syndrome
Cuffe MS et al.. Lancet Gastroenterol Hepatol 2025 · PMID 40258374 · DOI 10.1016/S2468-1253(25)00054-8Meta-analysisindependent cross-checkabstract checked★ key studyA review of 28 trials found that several diets, especially low-FODMAP and a starch- and sugar-reduced diet, improved IBS symptoms more often than usual eating.
Improvement only in a proportion of patients; no cure
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare diets for IBS.
- How was the study done?
Network meta-analysis of randomised trials.
- How many people, animals or samples were studied?
28 trials, 2338 patients.
- What was actually found?
Low FODMAP and starch/sucrose-reduced diets improved global symptoms; only low FODMAP improved bloating.
- How large was the observed effect?
Non-improvement RR 0.41 (starch/sucrose-reduced) and 0.51 (low FODMAP).
- What do the results mean in everyday life?
Changing diet can help many but not all people with IBS.
- What are the study's limitations?
Diet trials hard to blind; few trials for some diets.
- What does it say about Elawady's specific claim?
Supports that diet matters; does not support an 85% cure.
- Do the results apply to Germany and Europe?
Applies to European patients.
- What can explicitly not be concluded from this study?
Cannot show that bread removal alone cures IBS.
-
Healthy habits linked with less heartburn
Mehta RS et al.. JAMA Intern Med 2021 · PMID 33393976 · DOI 10.1001/jamainternmed.2020.7238Cohort studyindependent cross-checkfull text checked★ key studyWomen with five healthy habits had half the risk of developing weekly heartburn; normal weight mattered most.
Even all five factors prevent ~37%, not 85%
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Link lifestyle with new reflux symptoms.
- How was the study done?
10-year prospective cohort.
- How many people, animals or samples were studied?
42,955 US women.
- What was actually found?
Five healthy habits halved risk; about 37% of cases attributable.
- How large was the observed effect?
HR 0.50 (0.42-0.59).
- What do the results mean in everyday life?
Keeping a normal weight and a healthy diet may prevent many cases of heartburn.
- What are the study's limitations?
Self-reported, observational, mostly White women.
- What does it say about Elawady's specific claim?
Supports a role of habits but not 'largely caused by eating habits' or bread specifically.
- Do the results apply to Germany and Europe?
Likely applicable to Europe.
- What can explicitly not be concluded from this study?
Cannot prove that changing habits removes reflux.
-
UK guideline on heartburn and indigestion
National Institute for Health and Care Excellence (NICE). NICE guideline CG184 2014 (last updated 18 October 2019)Guideline / position statementindependent cross-checkfull text checked★ key studyNICE advises lifestyle changes and the lowest effective dose of acid blockers, but long-term full-dose treatment for severe inflammation or a narrowed gullet.
Bleeding requires same-day referral; diet is one element of care
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Guide care of reflux and indigestion.
- How was the study done?
National guideline.
- How many people, animals or samples were studied?
Adults in England.
- What was actually found?
Lifestyle first; step down PPIs; keep PPIs for stricture/severe oesophagitis; eradicate H. pylori in ulcers.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
Diet matters, but some people need acid blockers long term.
- What are the study's limitations?
Older evidence base for some statements.
- What does it say about Elawady's specific claim?
Contradicts a blanket ban on acid blockers.
- Do the results apply to Germany and Europe?
Applies directly to Europe.
- What can explicitly not be concluded from this study?
Not an evidence synthesis for each claim.
-
Warning signs that need a doctor
National Institute for Health and Care Excellence (NICE). NICE guideline NG12 2015 (last updated 15 April 2026)Guideline / position statementindependent cross-checkfull text checkedDifficulty swallowing, vomiting blood, or weight loss with reflux at 55 or older should be checked for cancer.
Dysphagia, weight loss, haematemesis need investigation, not diet trials
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Define when to suspect upper GI cancer.
- How was the study done?
National guideline.
- How many people, animals or samples were studied?
Adults in primary care.
- What was actually found?
Dysphagia, weight loss, haematemesis and anaemia trigger referral or endoscopy.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
Such symptoms must be checked, not treated by diet alone.
- What are the study's limitations?
UK thresholds.
- What does it say about Elawady's specific claim?
Supports the safety warning.
- Do the results apply to Germany and Europe?
Applies to Europe.
- What can explicitly not be concluded from this study?
Not about diet efficacy.
-
UK guideline on irritable bowel syndrome
National Institute for Health and Care Excellence (NICE). NICE guideline CG61 2008 (last updated 04 April 2017)Guideline / position statementindependent cross-checkfull text checkedNICE suggests regular meals, plenty of fluids, fewer fizzy drinks and possibly less high-fibre bread, with supervised diets if needed.
Red flags need referral; diet is not a universal cure
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Guide IBS care.
- How was the study done?
National guideline.
- How many people, animals or samples were studied?
Adults with IBS.
- What was actually found?
Diet and lifestyle advice first; low FODMAP with expert help; red flags referred.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
Food changes can help IBS, guided by professionals.
- What are the study's limitations?
Older diet evidence.
- What does it say about Elawady's specific claim?
Partly supports diet changes; contradicts 'drink only when thirsty' for IBS.
- Do the results apply to Germany and Europe?
Applies to Europe.
- What can explicitly not be concluded from this study?
Not proof of cure.
-
In a blind test, wheat was not clearly worse than a fake
Seiler CL et al.. Lancet Gastroenterol Hepatol 2025 · PMID 40706614 · DOI 10.1016/S2468-1253(25)00090-1Randomised controlled trialindependent cross-checkabstract checked★ key studyIBS patients who believed wheat or gluten made them ill had similar symptom flares after wheat, gluten or a look-alike sham bar.
Expectation explains much of perceived wheat effects; no evidence of near-universal response
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test whether wheat or gluten really trigger IBS symptoms.
- How was the study done?
Double-blind sham-controlled crossover trial.
- How many people, animals or samples were studied?
28 adults with IBS who felt better gluten-free.
- What was actually found?
Symptoms worsened in 39% (wheat), 36% (gluten), 29% (sham); not significantly different.
- How large was the observed effect?
RD wheat vs sham 0.11 (-0.16 to 0.35).
- What do the results mean in everyday life?
Expectations strongly shape symptoms; only some people truly react to wheat.
- What are the study's limitations?
Small; short challenges.
- What does it say about Elawady's specific claim?
Contradicts the idea that bread is the general cause of IBS.
- Do the results apply to Germany and Europe?
Applicable to Europe.
- What can explicitly not be concluded from this study?
Cannot exclude that a minority reacts to wheat.
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
Cutting sugar reduced acid reflux in a diet trial
Gu C et al.. Am J Gastroenterol 2022 · PMID 35973185 · DOI 10.14309/ajg.0000000000001889Randomised controlled trialindependent cross-checkfull text checked★ key studyIn 98 veterans with reflux, a diet much lower in simple sugars reduced oesophageal acid exposure over 9 weeks compared with a high-sugar diet.
Diet improves reflux measures, but no cure and no 85% response
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Carbohydrate type and reflux.
- How was the study done?
Randomised diet trial.
- How many people, animals or samples were studied?
98 veterans.
- What was actually found?
Less sugar, less acid exposure.
- How large was the observed effect?
AET -4.3% vs +3.1%.
- What do the results mean in everyday life?
Diet can help reflux.
- What are the study's limitations?
Mostly men; PPIs continued.
- What does it say about Elawady's specific claim?
Partly supports diet effects; not white-flour cure or stopping medicines.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Cannot show that stopping white flour replaces medication.
No study in this group is marked as key.
Regional context
Germany / EU
Not applicable.
Egypt
Not applicable.
What applies in my country?
General scientific assessment
Mostly false Unsupported promise: trials show improvement in roughly half of patients after weeks, not 85% within ten days, and no complete cure by stopping bread.
The following areas of food safety are relevant to this statement:
- Pesticides and pesticide residues
- Mycotoxins (mould toxins)
Cereals and rice
Choose a country to see the checked information for it.
Limits: legal rules describe what is allowed, not what every single food contains. Measurement data come from samples and are meaningful only together with their method details.
Country of residence or purchase Compare with another country
References
- ACG Clinical Guideline: Management of Irritable Bowel Syndrome.. Lacy BE et al.. Am J Gastroenterol 2021 · PMID 33315591 · DOI 10.14309/ajg.0000000000001036
- ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.. Katz PO et al.. Am J Gastroenterol 2022 · PMID 34807007 · DOI 10.14309/ajg.0000000000001538
- Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet.. Rej A et al.. Clin Gastroenterol Hepatol 2022 · PMID 35240330 · DOI 10.1016/j.cgh.2022.02.045
- The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis.. Bosman M et al.. Lancet Gastroenterol Hepatol 2021 · PMID 33765447 · DOI 10.1016/S2468-1253(21)00023-6
- Efficacy of dietary interventions in irritable bowel syndrome: a systematic review and network meta-analysis.. Cuffe MS et al.. Lancet Gastroenterol Hepatol 2025 · PMID 40258374 · DOI 10.1016/S2468-1253(25)00054-8
- Association of Diet and Lifestyle With the Risk of Gastroesophageal Reflux Disease Symptoms in US Women.. Mehta RS et al.. JAMA Intern Med 2021 · PMID 33393976 · DOI 10.1001/jamainternmed.2020.7238
- Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (NICE guideline CG184). National Institute for Health and Care Excellence (NICE). NICE guideline CG184 2014 (last updated 18 October 2019)
- Suspected cancer: recognition and referral (NICE guideline NG12), section 1.2 upper gastrointestinal tract cancers. National Institute for Health and Care Excellence (NICE). NICE guideline NG12 2015 (last updated 15 April 2026)
- Irritable bowel syndrome in adults: diagnosis and management (NICE guideline CG61). National Institute for Health and Care Excellence (NICE). NICE guideline CG61 2008 (last updated 04 April 2017)
- Effect of gluten and wheat on symptoms and behaviours in adults with irritable bowel syndrome: a single-centre, randomised, double-blind, sham-controlled crossover trial.. Seiler CL et al.. Lancet Gastroenterol Hepatol 2025 · PMID 40706614 · DOI 10.1016/S2468-1253(25)00090-1
- The Effects of Modifying Amount and Type of Dietary Carbohydrate on Esophageal Acid Exposure Time and Esophageal Reflux Symptoms: A Randomized Controlled Trial.. Gu C et al.. Am J Gastroenterol 2022 · PMID 35973185 · DOI 10.14309/ajg.0000000000001889